A Phase II Study of the HSP90 Inhibitor AUY922 in Patients With Relapsed and Refractory Lymphoma.

Trial Profile

A Phase II Study of the HSP90 Inhibitor AUY922 in Patients With Relapsed and Refractory Lymphoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Luminespib (Primary)
  • Indications Diffuse large B cell lymphoma; Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Nov 2016 Status changed from completed to discontinued.
    • 25 Jun 2015 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017 as per ClinicalTrials.gov record.
    • 19 Jun 2014 Status changed from active, no longer recruiting to completed as reported by M.D. Anderson cancer centre.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top